BerGenBio

BERGENBIO ASA: Invitation to first quarter 2020 results webcast presentation

Bergen, Norway, 13 May 2020 - BerGenBio ASA (OSE:BGBIO), will announce its

results for the first quarter 2020 on Tuesday 19 May 2020. A webcast

presentation by BerGenBio's senior management team will take place at 10 am CET.

The presentation will webcast live and the link will be available

at www.bergenbio.com in the section Investors/Financial Reports. A recording

will be available shortly after the webcast has finished.

The results report and presentation will be available at www.bergenbio.com in

the section: Investors/Financial Reports from 7:00 am CET the same day.

-Ends-

Contacts

Richard Godfrey CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs,

Consilium Strategic Communications

+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

+47 995 13 891

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad Phase II oncology clinical development

programme focused on combination and single agent therapy in lung cancer and

leukaemia. A first-in-class functional blocking anti-AXL antibody, tilvestamab,

is undergoing Phase I clinical testing. In parallel, BerGenBio is developing a

companion diagnostic test to identify those patient populations most likely to

benefit from bemcentinib: this is expected to facilitate more efficient

registration trials supporting a precision medicine-based commercialisation

strategy. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.

The company is listed on the Oslo Stock Exchange (ticker: BGBIO).

For more information, visit www.bergenbio.com

AI Terminal